FRM
BCRX icon

Fox Run Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Fox Run Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-38,697
Closed -$294K – 917
2025
Q3 		$294K Buy
38,697
+20,972
+118% +$175K 0.05% 692
2025
Q2 		$159K Sell
17,725
-11,700
-40% -$109K 0.03% 773
2025
Q1 		$221K Sell
29,425
-38,615
-57% -$311K 0.03% 770
2024
Q4 		$512K Buy
68,040
+27,406
+67% +$208K 0.09% 434
2024
Q3 		$309K Buy
40,634
+4,522
+13% +$34.4K 0.07% 528
2024
Q2 		$223K Buy
36,112
+17,594
+95% +$97.1K 0.04% 636
2024
Q1 		$94.1K Sell
18,518
-523
-3% -$2.94K 0.02% 708
2023
Q4 		$114K Sell
19,041
-6,435
-25% -$37.3K 0.03% 675
2023
Q3 		$180K Buy
+25,476
New +$183K 0.05% 580
2022
Q4 		– Sell
-19,854
Closed -$250K – 625
2022
Q3 		$250K Buy
19,854
+4,989
+34% +$64.2K 0.1% 410
2022
Q2 		$157K Buy
+14,865
New +$153K 0.08% 438
2017
Q4 		– Sell
-23,400
Closed -$123K – 671
2017
Q3 		$123K Buy
23,400
+700
+3% +$3.58K 0.03% 639
2017
Q2 		$126K Buy
+22,700
New +$138K 0.04% 587

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fox Run Management's BCRX Position: Q4 2025 in Review

Fox Run Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 38,697 shares — an estimated $294K sold.

Fox Run Management first reported a position in BCRX in Q2 2017 and held it in 13 quarters. The position peaked at $512K in Q4 2024. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Fox Run Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Fox Run Management sold 38,697 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $294K.
  • Fox Run Management first reported a position in BioCryst Pharmaceuticals in Q2 2017 and held it in 13 quarters.
  • Fox Run Management's BioCryst Pharmaceuticals position peaked at $512K in Q4 2024.
  • 272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.